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Background and Purpose—There is a lack of agreement regarding measuring the effects of stroke treatment in clinical
trials, which often relies on the dichotomized value of 1 outcome scale. Alternative analyses consist mainly of 2
strategies: use all the information from an ordinal scale and combine information from several outcome scales in a
single estimate.
Methods—We reanalyzed 3 outcome scales that assessed patient recovery (modified Rankin Scale, National Institutes of
Health Stroke Scale, and Barthel Index). With data collected from the 1652 patients in the Citicoline pooling data
analysis, we used 2 standard techniques of exploratory multivariate analysis to analyze the distances among ranks and
to isolate the common and the unique information provided by each of the 3 scales.
Results—The different scale values correspond to gradually different patient status, confirming that information is lost
when a scale is collapsed to just 2 values, whether recovered or not. The scales shared 90.7% (95% CI, 84.5–96.9) of
their information, with no individual scale contributing unique information.
Conclusions—Salient stroke outcome information is lost when an ordinal scale is collapsed into fewer categories. In
contrast, the full scales provide a comprehensive patient outcome estimate. Furthermore, in the context of stroke clinical
trials, those scales are highly correlated, providing the rationale to pool them into a single estimate. These insights may
be used to optimize the analysis of stroke trials to increase study power to detect efficacious interventions. (Stroke.
2010;41:e143-e150.)
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S troke is the second most common cause of death and amajor cause of disability worldwide.1 Although at least
178 randomized clinical trials enrolling .73 000 patients
were conducted for 75 promising agents over the 20th
century, only 3 trials reported positive findings and only 1
agent has been approved by the Food and Drug Administra-
tion for use in acute cerebral ischemia.2
The pivotal phase III clinical trial is used to guarantee
that only a small a-proportion of nonefficacious interven-
tions are approved for application to patients. Statisticians
have developed methods to maximize study power; that is,
the proportion of interventions with true biological effi-
cacy that are approved. In addition to the magnitude of the
intervention effect and the sample size, power is mainly
related to measurement reliability and statistical analysis.
Although patient recovery after stroke is routinely mea-
sured by ordinal outcome scales, the most popular statis-
tical analysis3 has been comparing the proportion of
recovered patients, defined as those with scores above a
single prespecified cut-point on a single outcome scale. As
Wardlaw et al4 have shown, “a change of a single point on
the Ranking scale can make the difference between ‘suc-
cess’ and ‘failure.’ of the trial.
In this article, we address 2 increasingly used though
controversial alternatives to the traditional, dichotomized,
single-scale analysis: (1) the use of the entire range of
information captured in an ordinal scale; and (2) the use of
more than just 1 single scale. For the former, opinions are
clearly divided between those in favor of using all the ordinal
information to maximize power5,6 and those in favor of
dichotomization because of its readability.7 If the scale is
truly ordinal—that is, if differences in scale categories are
related to some progressive degree of biological or clinical
difference in patient outcome— then some information is lost
when different categories are merged. The second contro-
versy confronts the classical univariate effect estimate based
on just 1 scale with an effect estimate based on information
pooled from several—often 3 to 4—scales (“global test”).8,9
The rationale is that if more information is used from every
patient, fewer patients would be needed. One regulatory
agency has argued that this global estimate causes difficulties
in its clinical interpretation10 and its explanation to patients.
An additional concern is how to interpret a single “global”
effect if discordant treatment effects are observed on each
component scale. The key point is whether those scales are
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measuring different patient characteristics or just 1 single
dimension of patient recovery.
We use 2 well-established methods of explanatory multi-
variate analysis to study 2 assumptions underlying alternative
methods. First is the existence of some progressive order
among the different outcome values of ordinal scales. Do
patients belong to just 2 alternative categories (success and
failure), or may they be ranked within the full scope? To put
it more simply, does an order make sense? Second is the
amount of common vs unique information provided by the 3
most usual scales. Does a combination of outcome scores
make sense, or does this pooling imply that some specific
information is lost? In addition, the correspondence among
values of different scales is provided.
Materials and Methods
Patient Population
We analyze the individual data pooled in a meta-analysis of
Citicoline,11 which merged 4 clinical trials conducted in the United
States between 1997 and 2001. They included 1652 patients with a
24-hour previous stroke. Main clinical and demographic character-
istics can be found elsewhere.11
Recovery Measures
Patients were assessed 12 weeks after stroke using the Modified
Rankin Score (mRS), the National Institute of Health Stroke Score
(NIHSS), and the Barthel Index (BI). The worst values on the NIHSS
(42), BI (0), and mRS (6) were imputed to the 275 patients who died
before 12 weeks had passed.
Bivariate Analysis of Ordering
To explore the existence of a genuine rank ordering of the levels
of each scale, we analyze if there is a trend in the central values
(means and medians) of 1 scale given the values of the other
scales (eg, we compare the mean NIHSS scores for patients rated
0–6 on mRs).
Simultaneous 3-Dimensional Analysis of Ordering
Multiple correspondences analysis (MCA) explores the relation-
ship between the categories of the different scales. It makes no
assumption about their order. For all cases in each scale category
(eg, mRS51), it computes its profile, that is, the percentage of
patients in each category of the remaining scales. Closer catego-
ries are expected to have more similar profiles. The degree of
dissimilarity between the profiles of 2 categories is quantified by
the x2 distance. Based on algebra analysis, MCA defines a new
multidimensional space and locates each category in this new
space to reproduce their original distances with the minimum
possible number of independent dimensions. As 2 analogies, the
distances among 50 European cities should be able to be plotted
in just 2 dimensions: north-to-south and east-to-west, but the
distances between 50 railway stations of the same line should be
able to be plotted in only 1 dimension. The French term “analyses
des correspondances” was used to denote a “system of associa-
tions” between the categories in a data set. Hence, there is an
agreement between the positions (in the new dimensions defined
by MCA) of the categories in terms of their association in the data
matrix. It has been used in the medical field to study the
interrelationships among risk factors12 and to reduce highly
correlated categorical variables to fewer but more significant
dimensions. For example, Briand13 reduced 5 exposure variables
to 1 aggregated exposure indicator. Islami14 constructed a com-
posite wealth score using multiple socioeconomic status assess-
ments. Here, we apply MCA to analyze the distances among the
successive ranks.
Common and Specific Information Behind the
3 Scales
The amount of common information shared by the 3 scales has been
quantify with principal component analysis (PCA). MCA and PCA
are very similar, with the difference being that the latter assumes a
measurement unit and then it is able to use means and variances.
PCA considers variability as information that allows differentiation
of patients. It defines a new dimension (component or factor)
that—as much as possible—retains the variability contained in the
original variables. The information not included in the first compo-
nent is then used to define a second component that, being indepen-
dent to the former, retains, again, as much information as possible.
PCA also provides an R2-like measure of the amount of original
information retained in the new space.
We also assessed the implications of unit measure and dichoto-
mization by comparing the values of the parametric (Pearson), the
rank (Spearman), and the dichotomized (Phi) correlation coefficients
between pairs of variables.
MCA and PCA have been implemented using version 5.6.0 of
SPAD (Syste`me Portable pour l’Analyze de Donne´es). Confidence
intervals (CI) have been computed by standard intensive jackknife
resampling methods using version 2.6.0 of the free software R.
Results
Description
In the 4 studies, 1652 patients were included and they provided
values for the 3 outcome scales. Figure 1 and Table 1 show the
shape and descriptive statistics of the 3 outcome scales.
Analysis of Ordering
Analyses of the means from 1 scale along the values of other
scales suggest the existence of a natural ordering within the
categories of 3 scales, with almost no ties and only some
minor discordant results (Figure 2).
Figure 3 shows the position, with CI, of each category
within the first MCA dimension. The BI value 100 is plotted
close to NIHSS and mRS values 0, 1, and 2. On the other side
of the new dimension, the 3 worst values of each scale are
represented together. Only 4 inversions have been observed:
2 on NIHSS (value 12 fell into position before 11; and 10 fell
into position before 8 and 9) and 2 inversions on BI
(categories 25 and 30, as well as 5 and 10). In the center we
found mRS value of 4, BI values of 25 and 30, and NIHSS
values of 8, 9, and 10.
Uniform Unit of Measurement
Spearman-Rank correlations among the 3 scales (Table 2)
ranged from 0.89 to 0.94, being slightly superior to the
Pearson unit-measure correlations of 0.84 to 0.90 but clearly
superior to the Phi correlation between the dichotomized
scales of 0.58 to 0.68.
Taking into account the numeric values of the 3 scales, the
first PCA component retained 90.7% (95% CI, 84.5%–
96.9%) of the overall information, quantified by the sum of
the 3 variances of the original 3 scales (Figure 4). The
remaining 2 components were quantitatively negligible (6.0%
and 3.3%) and qualitatively showed no pattern of information
specifically related to any scale.
Discussion
Scale Ordinality
Our results provide evidence that for the leading outcome
scales measured 12 weeks after stroke, the different values of
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each correspond to different patient status and those values
are gradually ordered. This finding supports the recommen-
dation of the European Agency for the Evaluation of Medic-
inal Products that “dichotomization of outcome (positive–
negative) is not recommended for neurological scales as
patients in the same category may be clinically distinct and
important information might be missed.”15
However, from a medical point of view, the objective
could be “whether subjects finish the study with minimal or
no disability” and, then, the main analysis may rely on the
proportion of patients reaching this goal. This medical objec-
tive should be weighted with the statistical objective of
maximizing the trial power, as well as the need to provide
regulators, clinicians, and patients with a readable treatment
effect measure.
The binary correlations in Table 2 are lower than those
reported by Tilley et al8 for the NINDS tissue plasminogen
activator stroke trial (0.67 vs 0.75 for mRS–NIHSS and 0.58
vs 0.67 for BI–NIHSS). In addition to random sample
variability, evaluator reliability, a different data imputation
strategy, or a more heterogeneous patient population (ie,
wider eligibility criteria, longer treatment delay, and so on)
can also explain this result. In any case, the benefit of
combining the univariate estimators in a single multivariate
one (as the Generalized Estimating Equations [GEE] does) is
higher for lower correlations.”16
Uniform Unit
Our results show that the scales are not linear (Figure 2), with
some clustering for the healthier scale values that may
suggest smaller information loss when pooling mRS of 0 with
mRS of 1 than when pooling from mRS of 2 to 6. However,
the assumption of a uniform unit has a limited impact in
correlation measures. In addition to the standard assumptions
of independent and identical randomly distributed variables,
the Pearson correlation coefficient also assumes a normal
bivariate distribution and a linear relationship among the
variables, but the Spearman correlation coefficient only
assumes a linear relationship among the ranks calculated
considering ties.
Any mathematical model is a simplification of nature, but
our data agree much more with the oversimplification of unit
measure (ie, that the difference between mRS51 and mRS52
equals the difference between mRS54 and mRS55) than the
oversimplification of dichotomization (ie, that patients with
mRS52 are equal to patients with mRS55). So, if in the
quest for simplification researchers agree to pay the smaller
penalty of unit measure, then parametric statistics may be
used to quantify treatment effect size, probably leading to
more powerful and readable analysis.
Figure 1. Univariate distributions for the outcome neurological
scales on day 90. The mRs is a global measure of disability and
handicap ranging from 0 (no symptoms) to 6 (death). NIHSS is a
neurological impairment scale ranging from 0 (no deficits) to 42,
rated by an expert neurologist. BI is a functional activities of daily
living scale ranging from 0 (completely disabled) to 100 (fully inde-
pendent), with only 21 possible values ending in 0 or 5 (eg, 0, 5,
10, . . . 95, 100). The mRS is more uniform than the other scales,
with a mode on the value of 4. NIHSS is skewed to the lowest val-
ues, although the worst value, 42, is strongly influenced by its
imputation to dead patients. BI is U-shaped, with values concen-
trated at both extremes. Imputed values to the 275 patients who
died are highlighted.
Table 1. Descriptive Statistics for the Neurological Scales on
Day 90
Median (IQR) Mean (SD)
mRS 3 (2) 3.1 (1.9)
NIHSS 6 (12) 11.9 (14.5)
BI 75 (90) 59.7 (40.8)
IQR indicates interquartile range.
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The assumption of uniform unit has been widely used
with those neurological scales. For example, scale means
have been provided in the description of one-fifth of stroke
clinical trials.17 In a review of their clinical interpreta-
tion,18 the NIHSS and BI reliability are quantified by the
unit-measure intraclass correlation coefficient. In a more
sophisticated way, the VISTA19 and the SAINT investiga-
tors20 used baseline NIHSS as a quantitative predictor
variable of outcome in 2 similar logistic regression. Joint
analysis of the 2 SAINT trials estimated that the odds of a
favorable outcome is expected to be systematically multi-
plied 0.814-times for each 1-point increment on the NIHSS
baseline, either in an increment from 1 to 2 or in an
increment from 21 to 22.
Common vs Unique Information
The scales have traditionally been used to assess the
different dimensions of health recognized by the World
Health Organization: physical deficits (NIHSS), functional
disability (BI and mRS), and social handicap (mRS).
However, they are highly correlated, and all of them can
also be conceived as measuring stroke recovery. Our
results show that 90% of the value differences on each of
the 3 scales reflect variation along a single common stroke
recovery dimension. Because the remaining variability
cannot be attributed to specific information indexed
uniquely by an individual scale, controversial clinical trials
results among scales are not expected. Furthermore, our
results support interpreting the 3 scales as repetitive
measures of the same parameter: patient recovery. As an
analogy, cardiologists average 3 repetitions of independent
determinations of blood pressure values to improve reli-
ability. For example, the CONSORT statement,21 in item
6b, requires specifying “any methods used to enhance the
quality of measurements (eg, multiple observations).” Our
estimated value of 90.7% of common variance can be
directly compared with the intraclass correlation coeffi-
cient obtained on blood pressure data. Montes et al22
estimated the concordance between a family doctor and a
semiautomatic device to be 0.84 (95% CI, 0.78–0.90). In
other settings, such as health-related quality-of-life mea-
sures, usual intraclass correlation coefficient values can
range23 between 0.55 and 0.79. The assumption of a
common correlation without specific contributions from
any scale has been used in simulations to explain the extra
power provided by the global statistic.16
Readability and Transparency
In choosing a statistical method, in addition to the medical
question and its statistical properties, its readability should
Figure 2. Progression of means over the scale values. Solid (broken) lines represent the means (95% CI) of the scale plotted on the vertical
axis depending on the values of the scale on the horizontal axis. Light gray lines represent the results for all patients, and the dark gray lines
represent the survivors subset (89 patients with the lowest BI value). The mRS (A, B) shows no inconsistencies in the progression of means
from the other 2 scales, although this “progression” is higher from 3 to 6 than 0 to 3. The pattern of NIHSS also shows a progression in the
means from mRS (C) and BI (D), with minor deviations in less-observed categories (eg, 10). BI shows a natural ordering when analyzing mRS
values (E) but some oscillations or minor inconsistencies in the less-observed categories (15–40) of NIHSS (F).
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also be considered to achieve the desired transparency to
enhance physician advice and patient choice. Our results
suggest that in the setting of clinical trials, the 3 outcome
scales can be seen as a repeated measure of the same clinical
feature: patient recovery. Provided that this assumption is not
violated in the actual clinical trial data (ie, that different
scales do not show true different estimations of effect size), it
facilitates the interpretation. For example, the GEE odds ratio
estimates a single treatment effect on “patient recovery” with
“minimal or no disability.”
To check the transparency and readability of the differ-
ent alternative statistical analyses, random surveys of the
general population of potential stroke patients, of patients
who have had a stroke, and of physicians who treat stroke
patients should be conducted to ask the various groups
what type of treatment effect size measure they find most
interpretable.
Limitations
External validity is maybe the most important limitation. To
reach its main objective (to get an unbiased estimate of the
treatment effect size), clinical trials rely on the random
allocation of treatments to patients fulfilling the eligibility
criteria. Because they are not based on random samples of
patients, the extrapolation of their results needs the additional
assumption that the treatment effect is still the same on the
external, more general, new target population. Because our
results rely on clinical trial data, we do not pretend that our
conclusions apply to other conditions. Specifically, in con-
trast to our results, it is highly plausible that the 3 outcome
scales should have a completely different meaning in settings
other than stroke trials. So, we do not propose that the 3 scales
should be interpreted as just measuring only 1 patient
characteristic in the general population. Furthermore, the 3
outcome scales we used were recorded 12 weeks after stroke
by evaluators blinded to treatment assignment but aware of
the other scale values, violating a key design feature for
Figure 3. MCA: first dimension.# MCA first computes the x2 distance between each pair of categories by comparing their profiles (that
is, the percentages of all remaining values). Second, it looks for the smallest dimension that better-reproduces those distances. The x2
distance between categories is a measure of dissimilarity between their profiles. #Other dimensions were negligible. The vertical axis
represents the first new dimension that could be interpreted as patient recovery. It has been rescaled to have a mean of 0 and stan-
dard deviation of 1. The bar length is the 95% CI and the center square is the 50% CI. The natural rank is highly preserved, but con-
secutive scale values related to healthier status (top) are plotted closer than those related to worse health conditions (bottom). As an
example of correspondences among values from different scales, mRS value 4 corresponds to values 9 and 35–40 on NIHSS and BI
scales.
Table 2. Correlations Between Pairs of Scales
Correlations
Unit Measure
(Pearson)
Ranks
(Spearman)
Dichotomized†
(Phi)
mRS–NIHSS 0.84 0.91 0.68
mRS–BI 0.90 0.94 0.67
NIHSS–BI 0.84 0.89 0.58
†mRS#1, NIHSS#1, BI$95.
Rank correlations are slightly higher than unit measure correlations but
much higher than their dichotomized version.
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measuring concordance and diagnostic performance.24 To
apply our results to other clinical settings, adequately col-
lected data should be analyzed.
In all of our analyses we have assumed that the equivalence
premise holds for all the scale values, that is, that patients
sharing the same scale value are identical among each other
but different from any other patient, at least in the measured
characteristic. This premise is intrinsic to any measurement,
irrespective of other measure properties such as rank or unit
measure. However, this assumption is highly questionable in
the case of the NIHSS scale. For example, a NIHSS of 3
could represent a major deficit in 1 area or a collection of 3
very minor deficits. Our analysis does not provide any
evidence about the correspondence between these 2 different
kinds of NIHSS of 3, but maybe a future MCA performed on
the different components of this scale could add some new
information. Taking into account the idiosyncrasies of stroke
patients, it should also be studied to see if they can help in
assessing the equivalence between those different NIHSS53
values.
In the interest of parsimony, our reported analyses have not
considered 3 variables that may potentially affect the distri-
bution of the outcome scales: study, allocated treatment, and
Treatment delay. When those 3 variables have been included
in our analyses, the results have been almost identical.
Implications for Phase III Clinical Trials
Our results point out that the frequent dichotomization of
ordinal scales merges scale values that correspond to different
patient status, suggesting the loss of power previously raised
by several authors, either by using theoretical formulas of
sample size3 or by reanalyzing previous stroke clinical
trials.25 However, Savitz et al26 found that the Cochran-
Mantel-Haenszel ordinal shift test failed to outperform the
dichotomized Rankin outcome of 0 to 2 in the post hoc
analysis of the NINDS and ECASS trials.
We have shown that the assumption of unit measurement
has a modest impact on results, allowing parametric statistics,
such as means and standard deviations, to display patient
evolution on any of those scales and using design features to
improve statistical efficiency (such as averaging repeated
determination of the same scale to control either inter-rater or
intrapatient variability). Researchers can avoid the assump-
Figure 4. Representation of the scales in the first 2 PCA dimensions. NIHSS, mRS, and inverted BI all extend in the same direction
along the first component, which can be regarded as patient recovery and accounts for 90.7% of the original variability. The exclusion
of patients who died resulted in a very similar pattern (dotted lines), with minor changes only in the second dimension, which confronts
the neurological information from NIHSS with the more general information from BI and mRS, but it accounts only for 6.0% of the over-
all information provided by the 3 scales. If the 3 variables had been fully independent, each new dimension would have retained one-
third of the original information provided by the 3 variables. In the other extreme situation when the 3 variables are perfectly correlated,
only 1 new dimension would retain 100% of the information. In such a situation, the 3 variables will order the individuals in exactly the
same manner, with exactly the same relative distance between consecutive cases.
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tion of a constant scale unit by using an ordinal analysis,
which retains much of the power and is less sensible to
extreme values. In ordinal analyses, treatment effect esti-
mates can take the form of odds ratios3 or the Mann-Whitney-
Wilcoxon c-statistic; that is, the proportion of patients having
better outcomes with the study intervention than with the
control,27 which is a single and interpretable measure of
stroke treatment effect.5,28
Our results also provide a foundation for merging estimates
from different scales. Because the scales do not statistically
measure unique dimensions, results in different directions
should not be encountered, and a single combined estimate
will increase study power. The O’Brien test may combine
quantitative variables from several outcomes.29 If the unit-
measure assumption does not hold, the adjusted O’Brien
rank–sum-type test can be applied to the ordinal outcome
scales.30
By interpreting the scales as repetitions of the measure-
ment of patient recovery, we pose the question of “adding
patients or adding measures,”31 because extra information can
also be provided by other scales, such as the Glasgow
Outcome Scale.
Conclusion
Our results suggest that the common practice of using a single
dichotomized scale in primary end point analysis is not
optimal, and it may result in reduced study power, making
trials needlessly larger or increasing the chance that studies
will fail to detect the benefit of a genuinely efficacious agent.
Our results indicate that more information can be used in the
statistical analysis of stroke trials if dichotomization is
avoided and several scales are joined to estimate a single
efficacy measure.
However, we have not studied the power of the suggested
methods under different alternative treatment effects. To
definitively boost the chances of improving stroke treatment,
statistical simulation studies should be performed to consider
the type of treatment effect of the new compound over the
comparator.
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